Leading with strength in the face of uncertainty.

Discover how breakthrough cancer research continues to help patients like Kara.

2021 Annual Report
Cancer is being conquered at The Princess Margaret because of donors like you.

One in two Canadians will be diagnosed with cancer in their lifetime. By the time the day is through, another 228 Canadians will die of cancer.

With stats like this, the end of cancer might seem very far away. But not to us. Canadians have a greater chance of surviving than ever before — the survival rate has jumped from 29% to 63% since the 1940s.

This progress is thanks to the dedicated cancer researchers and clinicians who continue to push the boundaries of knowledge, and because of generous donors like you.

In 2021, with the support of our passionate community, we granted $113 million to The Princess Margaret — more funds than ever before to fuel world-leading cancer care and research.

Princess Margaret Cancer Centre is transforming what it means to live with cancer — but these breakthroughs only happen with the support of donors like you.

The Princess Margaret at UHN is:

- Canada’s leading comprehensive cancer centre, fuelled by the country’s largest cancer charity.
- Treating more than 200 types of cancer, including many of Canada’s most complex and rare cases.
- Treating 19% of our patients in trailblazing clinical trials – almost double the national average of the US or the UK.
- Home to 300 of the world’s leading cancer researchers.
- Partnering with more than 500 leading cancer institutes in 107 countries to advance breakthrough cancer research, education, and care on a global scale.
The COVID-19 pandemic changed many things: the way we work, the way we live, the way we fundraise. One thing that didn’t change: the steadfast commitment of our supporters. Thanks to you, we were able to continue to build upon our commitment to conquering cancer. In a year of unprecedented challenges, the overwhelming support of our donors allowed us to continue to achieve world-class impact, delivering more funds than ever before to continue life-saving cancer research and patient care. We completed the first phase of the Cancer Centre’s Space Transformation. We celebrated several cornerstone gifts to the project, including Richard Rooney & Laura Dinner’s $5 million gift to support the new Patient Education Theatre, and a $5 million gift from the Myhal Family Foundation to support the new Blood Collection/ECG Lab on the first floor. The Longo’s Family Charitable Foundation stepped forward with an outstanding gift of $2.5 million to support our Space Transformation project and Tumour Immunotherapy Program. We also found innovative ways for our events to overcome the challenges of lockdown. Within months of the new government restrictions, our team worked swiftly to transition some of the country’s largest peer-to-peer events into virtual experiences. We even added new ways for supporters to engage with The Princess Margaret with the “almost anything goes” fundraiser, the DIY Challenge, and entered the e-gaming space with Quest to Conquer Cancer, inspiring support from an entire new community of supporters including 99% first-time donors with 77% from outside of Canada. Finally, our Princess Margaret Home Lottery achieved record-setting results, delivering $49.3 million of net revenue to fund cancer research. This past year required more strength, tenacity, and resilience than ever before. The enduring commitment of the Cancer Centre staff to patients was nothing short of remarkable. The support from our donors and community was beyond extraordinary. Together, we stood strong in the face of adversity and granted $113 million to the Cancer Centre to accelerate cancer research and care – a new record! Thank you to our donors, volunteers, and community members for your endless passion, commitment, and generosity. Together, we will Conquer Cancer in Our Lifetime.

A hello from our new President and CEO.

I am honoured to join the team at The Princess Margaret Cancer Foundation in support of Princess Margaret Cancer Centre at UHN, where I worked over 20 years ago. Like so many Canadians, I have seen the toll that cancer can take on individuals and families, including my own, and I believe that the Foundation will have exponential impact in the years ahead in creating A Healthier World. The time to act has never been more urgent, due to the anticipated wave of cancer cases caused by delayed screenings during the pandemic. I am excited to return to the UHN family and work with this world class team of clinicians, scientists, staff, patients, and our volunteers and donors to Conquer Cancer in Our Lifetime.

Dr. Miyo Yamashita, President & CEO, The Princess Margaret Cancer Foundation

A message from our leaders.

We’re committed to transforming the cancer experience and to making a dramatic improvement in cancer outcomes. But it is going to take all of us.”

Janice Fukakusa, Board Chair, The Princess Margaret Cancer Foundation
A Healthier World for cancer patients.

The UHN Vision to deliver A Healthier World means that we are deeply committed to providing just that for cancer patients. Despite decreases in cancer death rates in high-resource countries, the number of cancer cases and deaths is projected to more than double worldwide over the next 20–40 years. By 2030, there will be approximately 28 million new cancer cases and 17 million cancer deaths per year globally, with cancer overtaking heart disease as the leading cause of death. Delivering Cancer Care 2030 is a top UHN priority.

Fortunately, the complexity of cases handled at The Princess Margaret and across the University Health Network make us a national and international leader in discovery, education, and care in cancer. In fact, we have the largest hospital-based research program in Canada at UHN, with major research in oncology, as well as cardiology, transplantation, neurosciences, surgical innovation, infectious diseases, genomic medicine, and rehabilitation medicine. Patients at The Princess Margaret benefit from this multi-disciplinary approach, as multiple health teams from across UHN come together to care for our patients’ complex needs.

Our deep commitment to transforming lives through excellence in cancer care never wavered throughout the pandemic, thanks to the exceptional work of TeamUHN. As we move forward with the guidance of the Board of Trustees, The Princess Margaret Cancer Foundation Board, and our new President and CEO of the Foundation — as well as the passionate community of donors who support The Princess Margaret — we know we will successfully address both the urgent and emergent needs of patients with cancer and truly deliver A Healthier World.

Right: Dr. Kevin Smith, President and CEO, University Health Network

Left: Brian Porter, Chair of the UHN Board of Trustees, President & CEO, Scotiabank

Delivering world class results in an unprecedented time.

The ongoing pandemic has presented unprecedented challenges to the global cancer community, transforming how we deliver healthcare and conduct science, and how we connect with each other. Still, the continuing growth in new cancer cases has remained constant. For this reason, we cannot waver in our determination to advance treatment by understanding cancer at the most detailed level, and by accelerating discovery and innovation.

With 163 new clinical research studies last year and $254 million in research funding, Princess Margaret Cancer Centre is the only comprehensive cancer centre in Canada and one of the world’s best. Reflecting on the past year, our major highlights include setting up a new biotechnology company, launching The Princess Margaret Global Cancer Program to address the growing disparities in cancer treatment in Canada, and around the world, and accelerating discoveries in blood stem cells that give us clues about how cancers maintain stem-like properties that may later be re-activated and contribute to cancer reoccurring. Finally, we completed major renovations of the main floor of the Cancer Centre as well as the Gynecology and Palliative Care Clinics to create a more inviting environment.

I would like to acknowledge the thousands of dedicated supporters who help make our programs, research, and bold innovation agenda possible. We continue to give comfort and confidence to our patients and their families in one of the most challenging times of this century, and we will not stop our pursuit of transformative cancer care. I look forward to working with the new President and CEO of The Princess Margaret Cancer Foundation and all of TeamUHN.

Dr. A. Keith Stewart, MB ChB, MBA, FRCP(C)
Director, Princess Margaret Cancer Centre
VP Cancer, University Health Network
Breaking new ground at The Princess Margaret.

Cancer did not stop because of COVID-19 and neither did we. Despite the challenges of the pandemic, scientists at The Princess Margaret persevered and made exceptional breakthroughs that will transform what it means to live with cancer. Thanks to donors like you, our scientists are making headway in key areas of cancer research, including enabling earlier diagnoses and developing new precision therapies that will treat cancers with greater efficacy and less harmful side effects.

Here are four examples of the remarkable progress made this year at The Princess Margaret.

Overcoming drug resistance in “hibernating” cancer cells.

In a first of its kind study, Princess Margaret Cancer Centre scientist Dr. Catherine O’Brien and her team discovered that all cancer cells can enter a sluggish, slow-dividing state to survive the harsh environment created by chemotherapy or other targeted treatments. In the same study, the researchers show that novel therapeutic strategies specifically targeting cancer cells in this slow-dividing state can prevent cancer regrowth.

“There are examples of animals entering into a reversible and slow-dividing state to withstand harsh environments,” says Dr. O’Brien. “It appears that cancer cells have craftily co-opted this same state for their survival.”

“This gives us a unique therapeutic opportunity,” Dr. O’Brien continues. “We need to target cancer cells while they are in this slow-cycling, vulnerable state before they acquire the genetic mutations that drive drug-resistance. It is a new way to think about resistance to chemotherapy and how to overcome it.”

First in Canada: High-precision treatment for pancreatic cancer with the MR-Linac.

In February 2021, The Princess Margaret became the first centre in Canada to complete treatment for a patient with pancreatic cancer on the magnetic resonance imaging guided linear accelerator — also known as MR-LINAC.

This state-of-the-art radiation treatment combines a magnetic resonance imaging (MRI) scanner with a linear accelerator to guide radiation delivery in real-time. That means our clinicians can watch live as the beam of radiation enters the body and can guide the beam to precisely target the tumour, lessening damage to healthy surrounding tissue.

This innovative technology allows for high-precision treatment, enabling physicians to observe a tumour’s size, movement, and perimeter with greater clarity and adjust radiation delivery accordingly while a patient is being treated.

We congratulate the large interdisciplinary team of over 50 clinicians and researchers for this milestone achievement in Canadian medicine.

Princess Margaret researchers launch start-up aimed at detecting cancer with blood sample.

A simple blood test for cancer could be on the horizon with Adela, a start-up company launched out of UHN poised to advance precision-based, personalized medicine.

Based on the cutting-edge research of Drs. Daniel De Carvalho and Scott Bratman, both Senior Scientists at Princess Margaret Cancer Centre, Adela envisions a future where multiple cancers and other diseases could be detected by taking a simple blood sample. With UHN’s unique technology de-risking approach and with support from the donor-supported Princess Margaret Cancer Centre Innovation Acceleration Fund, Adela gained the confidence of five major investor partners and has attracted seasoned entrepreneurs to their leadership team. Together, they will further advance the innovative liquid biopsy technology for cancer detection and management first discovered at UHN.

Learn more about innovations like these at www.thepmcf.ca/latest-news.
Supporting Patient Caregivers:
Drs. Meredith Giuliani, Janet Papadakos, Sarah Hales, Rinat Nissim, Jennifer Croke and Breffni Hannon

Supporting Cultural and Linguistic Diversity:
Drs. Stephanie Lheureux and Alejandro Berlin

Technology-Enabled Healthcare Provider Well-Being:
Drs. Mary Elliott and Alejandro Berlin

Providing Psychosocial Support for All New Patients:
Dr. Madeline Li and Megan Wexler

Transforming the patient experience.

Innovation continues with The Princess Margaret Grand Challenges.

The Princess Margaret is ready to transform how people experience cancer. It’s time to supercharge the progress being made and move into a new era of cancer treatment where everything is easier, better, and simpler.

As part of these efforts, the Cancer Centre launched The Princess Margaret Grand Challenges in 2020 — made possible by contributions from our donors. This work is crucial as we focus our interconnected research to detect the disease earlier and treat it with less-toxic therapies, moving beyond chemotherapy while optimizing our digital assets and data to accelerate innovations in high-definition therapeutics. The competition includes a grant of $500,000, which allows winners to pursue their bold projects that will move us closer to completely transforming the patient experience.

---

Dr. Natasha Leighl

**Intercept Cancer Winner:**

This category focuses on detecting cancer before symptoms appear and intercepting it while it’s still curable. Dr. Leighl was awarded for her work in advancing the early detection of lung cancers, one of the deadliest cancers in the world. Her work harnesses liquid biopsy to predict those at higher risk of recurrence, leading to increased cure rates and minimizing harsh side effects for those at a lower risk.

Dr. Adrian Sacher

**Beyond Chemotherapy Winner:**

This category supports thinking that goes beyond chemotherapy towards more personalized and effective treatments without the harsh side effects. Dr. Sacher and his co-investigators are working to determine when patients are responding well to immunotherapy at earlier stages and can avoid chemotherapy altogether.

Drs. Aisling Barry and Philip Wong

**Digital Intelligence Winners:**

Reimagining the cancer patient experience is an essential part of innovating new treatments, this category recognizes advancements made by maximizing digital intelligence. In what may be a world-first, Drs. Barry and Wong are using space technology to help palliative care patients. Their project will track patients using a Hexoskin smart shirt and virtual appointments with the potential of changing the dynamics of cancer care.

Dr. A. Keith Stewart, MB.ChB, MBA, FRCPC

**Human Touch in Cancer Care Winners:**

This category supports approaches that look to infuse comfort and confidence into every interaction a patient has, with a focus on equity, access, diversity, engagement, inclusivity, and communication. Grants were awarded to four distinct approaches:

**Supporting Patient Caregivers:**
Drs. Meredith Giuliani, Janet Papadakos, Sarah Hales, Rinat Nissim, Jennifer Croke and Breffni Hannon

The multi-disciplinary team behind this winning project is developing a program to provide family caregivers with comprehensive education, support, and skills they need to best care for themselves as well as their friends or family members who are suffering from cancer — creating the potential to transform support access for caregivers around the world.

**Supporting Cultural and Linguistic Diversity:**
Drs. Stephanie Lheureux and Alejandro Berlin

This project combines iPads, e-interpreters, and translated questionnaires to improve access to cancer care and the experience of cancer in patients with cultural and linguistic diversity, since research shows that having medical interpreter services improves both patient satisfaction and health outcomes.

**Providing Psychosocial Support for All New Patients:**
Drs. Aisling Barry and Philip Wong

Psychosocial care is of great value to cancer patients and their families — but it is often only delivered after distress occurs and to those most able to ask for it. Using technology, volunteer support, virtual and in-person education, and multiple communication approaches, this project will implement a multi-pronged strategy to achieve universal access to psychosocial services for all patients at The Princess Margaret.

**Technology-Enabled Healthcare Provider Well-Being:**
Drs. Mary Elliott and Alejandro Berlin

BRITe (Building Resilience within Institutions Together with Employees) was developed at The Princess Margaret to improve and sustain the well-being of healthcare providers, and this project seeks to expand it digitally. The BRITe app, a new digital extension of the program, will allow for on-demand access, personalization, and data collection to respond to the ever-increasing need from healthcare workers for support.
A new $10 million commitment from Agnico Eagle Mines will take cancer innovation at The Princess Margaret to the next level. For Sean Boyd, Vice-Chairman and CEO of Agnico Eagle, it is vital support that will help millions of people living with cancer. “Now more than ever, support from Corporate Canada has never been so critical to help accelerate life-saving cancer research and to improve the quality of life for so many,” he says. Boyd hopes that the high-impact work accomplished through their partnership will inspire other Canadian corporations to make similar meaningful investments.

This latest $10 million commitment from the Canadian gold mining company brings their total support of the Foundation to more than $25 million, signaling their vision for reinforcing Canada as a world leader in the mission to conquer cancer. More specifically, this gift is leading to the creation of two Agnico Eagle Princess Margaret Grand Challenges grants, which will drive leading-edge cancer research in two key areas: early detection and less-toxic treatments.

In the first area, the Agnico Eagle Intercept Cancer Grand Challenge will support research methods to detect cancer at curable stages, even before symptoms appear. Early detection, diagnosis, and intervention against cancer offers the strongest chance of survival for patients, improving the cure rate of most cancers five- to ten-fold. The longer-term goal of this challenge is to establish a world-leading early detection and cancer intervention program, benefiting patients here in Canada and around the globe.

For the second area of focus, the Agnico Eagle Beyond Chemotherapy Grand Challenge looks to accelerate efforts to eliminate the debilitating side effects for patients. This challenge supports the research of options to deliver less-toxic, more precise, and more personalized treatments. On top of that, the goal is to use Princess Margaret Cancer Centre’s world-class expertise and infrastructure to position Canada as a global leader in the development of next-generation cancer therapeutics.

Discoveries made in each area will be put to the test in the Centre’s globally renowned clinical trials program, which transforms research into real results for patients. The Princess Margaret leads the world in this area, with 19% of patients in clinical trials — nearly double the number in the U.S. and U.K.

With capabilities like these, it is no surprise that Agnico Eagle sees the kind of meaningful support their company can bring. “For Agnico, we look to prioritize our social investment in areas that show promise of greatest impact,” Boyd continues. “And The Princess Margaret fits the bill, leading the world in advancing cancer discoveries, diagnoses, and treatments to cure more patients and improve quality of life of those living with cancer.”

Everyone at The Princess Margaret would like to express our deepest gratitude for Agnico Eagle’s visionary gift, which will allow us to not only showcase Canadian excellence and leadership for cancer innovation on the world stage, but which we believe will also inspire other major gifts from corporate Canada.
The Myhals make a cornerstone contribution.

For George and Rayla Myhal, investing in their community is of great importance, having supported many important institutions in health care, education, and culture. And, like so many of us, their lives have been touched by cancer. Having served as a Senior Managing Partner and Officer of Brookfield Asset Management Inc., George understands the importance of a well-designed space. This is why George and Rayla made a pledge of $5 million to our Space Transformation Campaign. Their generous gift will support innovation in the new Myhal Family Blood Collection/ECG Lab — a hub for every patient’s journey.

The new Myhal Family Blood Collection/ECG Lab features 14 private draw stations, charging stations for mobile devices, and ample seating for all. “We have long known of the world-leading breakthrough discoveries at The Princess Margaret,” say George and Rayla Myhal. “It is a research powerhouse that we, as Canadians, can be proud of. Improving this space helps thousands of patients, caregivers, and staff, who are at the Cancer Centre every week, while supporting great scientific discovery.”

Thank you, George and Rayla, for helping us lead the way.
Supporting cancer research runs in the Longo family.

The Longo’s Family Charitable Foundation (LFCF) was established with a vision to build happier and healthier communities. That mission has been accomplished through several strategic investments in healthcare and the community.

Their connection to The Princess Margaret began in 2011, when the Longo family lost father, uncle, mentor, and friend Tommy Longo to leukemia. “He was so many things to so many people, and The Princess Margaret played a critical role in his care. Our entire family is forever grateful for that. It’s a privilege to have world-renowned care in our own backyard,” says Rosanne Longo, Chair of the LFCF.

That same year, Longo’s cemented their commitment to conquering cancer by becoming the founding sponsor for Road Hockey to Conquer Cancer, one of our biggest peer-to-peer fundraising events. And in September of 2020, Longo’s and the Longo’s Family Charitable Foundation renewed that commitment by making a monumental $2.5 million donation.

“Road Hockey has been an incredible event; it brought our family together to honour Uncle Tommy and we now have our own division with eight teams and 20 volunteers that come out to help fuel the participants. Together, we’ve raised over $1.4 million and have re-committed to help conquer cancer.”

—Rosanne Longo

The recent gift will be split between two major areas of impact, one being the Tumour Immunotherapy Program and the other, the Space Transformation Project.

“We know that cancer doesn’t stop in the middle of a pandemic, and we have made it our mission to support the organizations leading the way in disease prevention” says Anthony Longo, President and CEO of Longo’s.

We at The Princess Margaret are forever grateful for the support of the Longo family and would like to acknowledge their generosity and commitment to helping us accelerate research, education, and clinical care here in Canada and around the world.

Thank you, Longo family, for being a valiant partner in our mission to conquer cancer.
Your front row seat to the future of cancer care.

Invest in Research

Want a say in the next big breakthrough in cancer research? When you support the Invest in Research program at The Princess Margaret, you join a select group of investors who work directly with some of the brightest minds at the Cancer Centre to decide which ideas will help shape the future of cancer.

Every year, the Invest in Research program reviews a short list of candidates working on new and innovative cancer research projects. From that list, donors vote on which projects will be granted $100,000 to embark on their bold and innovative ideas. While all advancements in research have the potential to create impact, this program focuses on funding higher-risk research that has the potential for much higher rewards.

This past year, thanks to the exceptional generosity of our investors, we were able to award grants to three promising research projects:

**Dr. Geoffrey Liu**'s project is focusing on earlier detection of lung cancer that could be quickly integrated into existing screening programs across Canada and around the world.

**Dr. Catherine O'Brien** is leading a project which aims to target and destroy cancer cells before they "hibernate" and resist chemotherapy, which may yield advancements for colorectal cancer patients.

**Dr. Anna Spreafico** and her team are seeking to improve our ability to predict which melanoma patients are at high risk of recurrence in order to plan more personalized therapy or avoid unnecessary treatments altogether.

To date, Invest in Research has raised $2 million in donations with our investors having funded 25 projects, each one holding promise that will one day help us conquer cancer. To learn more about these projects and about the impact you can make with this program, visit thepmcf.ca/Invest-In-Research.

---

"Your investment today will do more than help us stay on track. It will help fund the daring and bold ideas that change the way cancer is treated here in Canada and around the world."

—Dr. Aaron Schimmer, Director of Research, Princess Margaret Cancer Centre

Ready to invest? Contact Karina Wong, Manager, Leadership Giving, Karina.Wong@thepmcf.ca

Learn more about the impact of seedfunding at: thepmcf.ca/Invest-In-Research
Funded in 2015, The Till & McCulloch Society honours supporters who have cumulatively contributed $1 million or more to advance the future of cancer care at The Princess Margaret. These visionary supporters provide our clinicians and researchers with the resources to explore new ideas, drive breakthroughs, and offer the best possible care to patients.

Supporters like Fred and Vicki Tomczyk, who joined the society in 2013. This past year, the couple renewed their commitment to The Princess Margaret by investing in a program that uses non-invasive technologies and artificial intelligence methods to monitor cancer patients with the highest risk of cancer relapse. The program will also aim to enable effective interception strategies to prevent relapse and ultimately cure these patients.

We are extremely grateful to the members of the Till & McCulloch Society for sharing in our mission to Conquer Cancer in Our Lifetime.

For more information about becoming a member, please contact T&MSociety@thepmcf.ca.

"Funding the research that helps to detect and treat cancer in a timely, less intrusive manner is of the utmost importance to us. It has been an incredibly rewarding experience to follow the brilliant research team knowing that we are helping to provide hope for future generations."

— Fred & Vicki Tomczyk

Vicki and Fred Tomczyk.
With your support, we redefined our events.

"This year, I committed to participate in the Ride to Conquer Cancer for the first time. Even though COVID-19 altered the original event, it did not diminish the overwhelming feeling of camaraderie, support, and togetherness. I was taken aback by the lasting impact it has had on me.”
—Lisa Harris, first-time Ride participant

Even through uncertainty, our donors and supporters came through.

The 2020 events season didn’t play out exactly as we had envisioned. While many fundraising events around the world were cancelled, we were determined to find ways to engage meaningfully (and safely) with our dedicated participants. Your ongoing support gave us the confidence to move forward with modified versions of each of our events, plus some new virtual initiatives. We can’t thank you, our passionate community, enough for your commitments through this challenging year that continues to have a transformational effect on the lives of cancer patients.

Despite COVID-19, this year our events saw:

- **12,000** registered participants who joined us from **27** countries
- **$46.4M** net lottery revenue
- **$13M** to raise

**Muskoka’s premiere cycling event went virtual in 2020, allowing riders from across Canada (and as far away as Germany) to ride for cancer research.**
NorthernPass.ca

**This new initiative saw gamers raising money in Canada’s largest streaming fundraiser, with most donations coming from supporters outside of Canada!**
QuestToConquerCancer.com

**Our signature walking event, now 18 years strong, saw more than 1,600 walkers lace up for our first-ever virtual event.**
WeekendToConquerCancer.ca

**Journey held its final walk, raising a total of $11 million since it began. Our epic supporters will carry its spirit forward as part of The Weekend to Conquer Cancer™.**
TheEsbright™ Ride to Conquer Cancer® went virtual for the first time in 13 years, with more than 4,000 riders creating their own adventures across the country and beyond.
Ride2Conquer.ca

**The world’s largest road hockey fundraiser went virtual in 2020 with Legends Go Live, an online contest with 21 unique celebrity experiences.**
RoadHockeyToConquerCancer.ca

**For 25 years, The Princess Margaret Home Lottery has been giving away one big prize after another, raising millions for critical cancer research. Not even COVID-19 could stop that, with this year bringing record-setting sales.**
PrincessMargaretLotto.ca
Thank you to our Cancer Centre colleagues.

COVID-19 affected every aspect of healthcare in Canada and around the world. At The Princess Margaret, this was no exception. Our healthcare staff at the Cancer Centre was stretched and challenged like never before. The demands of the pandemic have been exceptional, and yet, our colleagues displayed a remarkable level of resilience and determination to put the needs of patients first. For this ongoing dedication, we are eternally grateful for their service.

How You Supported our Cancer Centre

We launched the Conquer COVID for Cancer Fund to support our Cancer Centre partners. Thanks to the kindness of our community, we generated a remarkable $1.8 million. Here's how you helped:

- You provided patients with tablets that kept them safely connected with loved ones
- You provided hot meals, free parking, and nearby accommodations to our healthcare team when they needed it the most
- You helped our Smart Cancer Care team deliver seamless virtual care to limit the potential for patient COVID exposure, while upholding an excellent standard of care (85% of patients said that the quality of care was comparable or better than in-person visits*)
- You helped fast-track crucial COVID-related clinical trials, allowing our researchers to contribute to the global race to understand and contain the virus

* Results from research study led by Dr. Berlin, published in JAMA Oncology in January 2021

The Rose Dean Essence of Oncology Nursing Award

Every day across The Princess Margaret, oncology nurses go above and beyond to provide exceptional support, compassion, and care for patients, their families, and caregivers.

This award is presented annually to an oncology nurse in recognition of their outstanding contribution to nursing within the cancer program aligned with the "best of nursing" themes. This includes the power of presence and truly "being with" patients and colleagues, providing excellent practice, and fostering an environment that enables nurses to be their best.

We are thrilled to recognize Nicole Sommerville as the 2021 award recipient. Nicole provided exceptional patient care and expertise while starting a new role in head and neck cancer, all while navigating the uncertainty and stress of the pandemic.

The Gerald Kirsh Humanitarian Awards

These awards are a longstanding event that allows us to recognize and honour the compassionate care that is so integral to The Princess Margaret patient experience. We are thankful to the Kirsh Family, who had the vision to establish this important award after having experienced exceptional care by the Cancer Centre’s staff and volunteers who cared for their father and husband, Gerald.

While this year’s ceremony was a virtual one, it was no less impactful. We honoured these three staff members who went above and beyond the call of duty to provide outstanding care.

(From top to bottom) Dr. Madeline Li, Psychiatrist; Robin Forbes, Social Worker; and Dr. Jennifer Croke, Radiation Oncologist.
For Suzanne Ramsay, the choice was always love.

For more information or to tell us you’ve made a gift in your will, contact Jill Nelson, AVP Estates and Gift Planning.

jill.nelson@thepmcf.ca • 416-738-7329

Suzanne met Jim in university. “She was a brilliant academic.” Excelling her way through school, emerging a passionate teacher of French immersion and student of life. “Madame Ramsay maintained a lifetime of learning, and teaching, wherever she went she taught and changed lives,” Jim says.

Following a passionate and dedicated career, Suzanne established her own wellness business. The Ramsays then designed and built a summer home on PEI, one known to friends as a “little piece of heaven.” Suzanne had time to paint, to garden, and together they lived a healthy, active lifestyle. Suzanne also gave inspirational talks to women. “She taught me how to stop and smell the flowers. Her energy was endless,” remembers dear friend Eynat. For the Ramsays, life was everything they hoped it to be, but in the fall of 2015, things changed.

After a trip to the Magdalen Islands, Suzanne noticed a lump in her abdomen, and it was growing fast. Immediate tests led to a heartbreaking discovery: ovarian cancer. The diagnosis affected everyone. “When your wife has cancer, you have cancer, we had cancer,” Jim says.

That winter, Suzanne faced an extensive surgery that brought with it complications. But even on her most challenging days, her outlook was exceptional. “She was teaching by example,” Jim says, “remaining positive and caring with everyone involved.” He often said that he was proud of Suzanne, to which she always replied “I am so proud of you, Jim. You’re the one that must watch.”

“Suzanne’s wish was to support all women affected by cancer.”
—Jim Ramsay

Suzanne began an aggressive chemo cycle, which worked for some time, but when the cancer came back, she underwent tests to see if she would be a suitable candidate for clinical trials. She was accepted, and Dr. Stéphanie Lheureux intervened with a new drug combination that controlled her cancer for close to 14 months. The Ramsays traveled to France and continued living life to the fullest. Unfortunately, the cancer metastasized, making its way to Suzanne’s brain. After 52 years together, Jim said his goodbyes to Suzanne, and the news of her passing ripped like a tidal wave. She is achingly missed.

By leaving an extraordinary gift in his will, Jim was able to fulfill Suzanne’s wish of providing easier access to clinical trials and empowering all women facing gynecological cancers. The donation will put patient needs front and centre by decreasing systematic barriers to participation. Dr. Lheureux is already leveraging the momentum of virtual care to intervene.

“Suzanne’s wish,” Jim says, “was to support all women affected by cancer. Many women are faced with this horrific diagnosis, but she always believed in choice. Suzanne knew that how you respond is critical to how you live.”

Throughout life, Suzanne was governed by positive affirmations and the choice of love was never more evident than when facing the ultimate challenges of her own cancer. She made a difference in every facet of her life, and will continue to do so for other women facing ovarian cancer through this gift.

“Suzanne and I shared an understanding. Life was immediate and full if we chose to make it so.” —Ovarian cancer patient and friend, Donna.

For more information or to tell us you’ve made a gift in your will, contact Jill Nelson, AVP Estates and Gift Planning.

jill.nelson@thepmcf.ca • 416-738-7329

Donor Story: Suzanne and Jim Ramsay

14
With deep gratitude to Janice and welcome to Richard.

We are delighted to welcome Richard as incoming Chair. The Chief Investment Officer of Burgundy Asset Management Ltd. for over 20 years — now Vice-Chair and Co-Founder — Richard has been a steadfast supporter of The Princess Margaret, in addition to holding leadership positions on the boards of other prominent Canadian foundations. We know Richard will bring great dedication to this role, having first joined the Foundation’s Board of Directors in 2017, and look forward to working with him to support the world-class impact delivered by The Princess Margaret.

On behalf of our entire community, we thank you, Janice, and say a warm welcome, Richard!
University Health Network (UHN)

April 1, 2020 to March 31, 2021

Elected Trustees (Voting)

Brian J. Porter
Board Chair
President and Chief Executive Officer
Stollery Children’s Hospital

Rosa Baker
Professor, Institute of Health Policy,
Management and Evaluation
University of Toronto

Dean Connors
President and Chief Executive Officer
Sun Life Financial

Todd Halpern
President
Halpern Enterprises

Stu Kedwell
Senior Vice-President & Senior Portfolio Manager, Co-Head North American Equities
RBC Global Asset Management

Peter Menkes
President, Commercial/Industrial Division
Menkes Developments Ltd.

Lawrence Pentland
Former Executive
Dell Inc.

Janet Rossant
Professor
SickKids
Senior Scientist

Mark Saunders
Former Chief of Police
Toronto Police Services

Shelley Sharkey
Chief Executive Officer
SE Health

Barbara Stymiest
Corporate Director
StakEras Ltd., George Weston Ltd.,
Sun Life Financial

Ajay Virmani
President and CEO
Cargojet

Peter Wallace
Secretary of the Treasury Board
Government of Canada

Jaime Watt
Executive Chairman
Navigator

Government of Canada
Secretary of the Treasury Board

Peter Wallace
Secretary of the Treasury Board

Governor of Canada
Secretary of the Treasury Board

UHN Board of Trustees

Brian J. Porter, Board Chair, UHN Board of Trustees

Kevin Smith, President and CEO, UHN

Trustees Appointed by U of T

Cheryl Regehr
Vice-President & Provost

Trevor Young
Dean, Faculty of Medicine
& Vice-Provost

Janis Fukakusa
Chair

Raj Kothari
Chair

Patricia Murphy
Chair

Mark Osten
President

Joy Richards
Vice-President Patient Experience & Chief of Health Professions

Kevin Smith
President & CEO
University Health Network

Chairs

A Chair is the highest honour in academic life, prestigious for Chairholder and donor alike. Our Chairholders are recognized internationally for superior academic achievement, experience and success in teaching and research. A sincere thank you to our donors who fund these prestigious positions.

List as of September, 2021

University Health Network (UHN)

April 1, 2020 to March 31, 2021

Princess Margaret Cancer Centre Held Chairs

AMGEN Chair in Cancer Research
Dr. Robert Rottapel

Barnett-Simth Whitman Chair in Radiation Oncology
Dr. John de Vries

Bartlett-Erginer Chair in Medical Oncology
Dr. Amit M. Vora

Baxter/Scott Chair in Cell Therapy and Transplantation
Dr. Jonas Mattsson

Baxter/Scott Chair in Tissue Engineering/Neuro-Oncology
Dr. Robert Rottapel

Baxter/Scott Chair in Cancer Survivorship Research
Dr. Jennifer Jones

Baxter/Scott Chair in Lung Cancer Translational Research
Dr. Ming S. Fong

Baxter/Scott Chair in Cancer Medicine
Dr. Keith Stewart

Baxter/Scott Chair in Genomics: Cancer Research
Dr. Sarah Ferguson

Dr. Mariano Antonio Eta Chair in Head and Neck Cancer Research
Dr. Scott Braman

Dr. Abe Lees Fellowship Chair in Kidney Cancer Research
Dr. Anthony Foss

Dr. Shear and Mary Fiset Family Chair in Radiation Physics
Dr. Jan Seidelmann

Gaffens Chair in Breast Surgical Oncology
Dr. Tuite CT

Gibson Chair in Oncology Pathology
Dr. Fer-Liu

JCI/Grant Chair in Oncology Pathology
To be appointed

Kabul Prince Family Chair in Chemosurgery/Head and Neck Surgery
Dr. Taylor G. Gilmour

Kirchmann Family Chair in Neuro-Oncology Research
Dr. Warren Weldon

K. T. Lo Chair in Prostate Cancer Research
To be appointed

Leukemia and Marrow Transplant Chair in Breast Cancer Research
Dr. Rachel N. Neuberg

Reid and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care
Dr. Camilla Zimmermann

Witkind G. Lestin Chair in Pancreatic Cancer Research
Dr. Jennifer J. Knox

The Love Chair in Prostate Cancer Prevention Research
Dr. Neil Fleshner

The Adie MacNaughton Chair in Thoracic Radiation Oncology
Dr. Alexander Sutin

Philip S. Orsino Chair in Lymphoma Research
Dr. Mark D. Minden

CIP/Pharmaceutical Foundation Chair in Cancer New Drug Development
Dr. Natasha B. Leighl

RBC Chair in Nursing Oncology Research and Education
Dr. Samantha Magee

Kun and Sandy Sibony Family Chair in Surgical Oncology
Dr. Jonathan R. Reznik

Joseph and Toby Tenenbaum/Brasil Family Chair in Prostate Cancer Research
Dr. Houshang Haji

The Weekend to End Breast Cancer Chair in Breast Cancer Research
Dr. Tan W. Mak

Weidlein/Cromwell Family Chair in Image Guided Prostate Therapy Research
Dr. Jonathan Reznik

Welshies Chair in Ovarian Cancer Research
To be appointed

The Robert E. Whitson Chair in Head and Neck Surgery
Dr. Patrick J. Gullane

The Robert E. Whitson Chair in Reconstructive Plastic Surgery
Dr. Steven D. Holler

Joint Chairs At University Health Network

Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation
Dr. Jonathan Reznik

Perz/Teinemaa Chair in Prosthetic Dentistry
To be appointed

The Anne and James Wellington Chair in Gastrointestinal Surgery
Dr. Richard G. Warshaw

Pessin/Garcia Chair in Thoracic Surgery
Dr. Thomas Waddell

Scotianski Research Chair
Dr. David Brooks

Simpson Taylor Chair in Lung Cancer Research
Dr. Francois Van den Bogaert

Tallon Scott Chair in Head and Neck Surgery
Dr. Jonathan W. Reid

To be appointed

Chairholders

Dr. Robert Rottapel

Dr. John de Vries

Dr. Amit M. Vora

Dr. Jonas Mattsson

Dr. Robert Rottapel

Dr. Jennifer Jones

Dr. Ming S. Fong

Dr. Keith Stewart

Dr. Sarah Ferguson

Dr. Anthony Foss

Dr. Jan Seidelmann

Dr. Tuite CT

Dr. Fer-Liu

To be appointed

Dr. Taylor G. Gilmour

Dr. Warren Weldon

To be appointed

Dr. Rachel N. Neuberg

Dr. Camilla Zimmermann

Dr. Jennifer J. Knox

Dr. Neil Fleshner

Dr. Alexander Sutin

Dr. Mark D. Minden

Dr. Natasha B. Leighl

Dr. Samantha Magee

Dr. Jonathan R. Reznik

Dr. Houshang Haji

Dr. Tan W. Mak

Dr. Jonathan Reznik

Dr. Houshang Haji

To be appointed

Dr. Patrick J. Gullane

Dr. Steven D. Holler

Dr. Jonathan Reznik

To be appointed

Dr. Jonathan Reznik

To be appointed

Dr. David Brooks

Dr. Francois Van den Bogaert

Dr. Jonathan W. Reid

To be appointed
Financial Summaries

5-Year Overview

Each year, The Princess Margaret Cancer Foundation reports on the funds it raises and stewards in two ways: via Audited Financial Statements (AFS) online at www.thepmcf.ca, and via the standard CRA T3010 form required of all not-for-profit organizations and found on the CRA website at canada.ca/en/services/taxes/charities.html. While both formats utilize the same financial information, The Foundation’s AFS provides a more detailed look, to better assess and control our financial performance.

Statement of Revenue, Expenses and Changes in Fund Balances ($ Thousands)

<table>
<thead>
<tr>
<th>Year ended March 31</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Fundraising Revenue</td>
<td>95,202</td>
<td>98,590</td>
<td>91,822</td>
<td>122,861</td>
<td>85,898</td>
</tr>
<tr>
<td>Direct Fundraising Expenses</td>
<td>(14,990)</td>
<td>(16,237)</td>
<td>(21,998)</td>
<td>(24,434)</td>
<td>(15,859)</td>
</tr>
<tr>
<td>Net Fundraising</td>
<td>80,212</td>
<td>82,353</td>
<td>69,824</td>
<td>98,427</td>
<td>70,039</td>
</tr>
<tr>
<td>Gross Lottery Revenue</td>
<td>72,334</td>
<td>78,897</td>
<td>88,239</td>
<td>102,904</td>
<td>113,170</td>
</tr>
<tr>
<td>Direct Lottery Expenses</td>
<td>(44,640)</td>
<td>(49,170)</td>
<td>(54,627)</td>
<td>(61,322)</td>
<td>(66,772)</td>
</tr>
<tr>
<td>Net Lottery</td>
<td>27,694</td>
<td>29,727</td>
<td>33,612</td>
<td>41,582</td>
<td>46,398</td>
</tr>
<tr>
<td>Net Fundraising and Lottery Revenue</td>
<td>107,906</td>
<td>112,080</td>
<td>103,436</td>
<td>140,009</td>
<td>116,437</td>
</tr>
<tr>
<td>Investment Income (Loss)</td>
<td>45,006</td>
<td>31,561</td>
<td>36,964</td>
<td>(5,153)</td>
<td>114,444</td>
</tr>
<tr>
<td>Net Revenue, including Investment Income</td>
<td>152,912</td>
<td>143,641</td>
<td>140,400</td>
<td>134,856</td>
<td>230,881</td>
</tr>
<tr>
<td>General Fundraising and Administrative Expenses</td>
<td>(11,287)</td>
<td>(12,467)</td>
<td>(9,603)</td>
<td>(9,743)</td>
<td>(10,886)</td>
</tr>
<tr>
<td>Excess of Revenue over Expenses before Grants</td>
<td>141,625</td>
<td>131,174</td>
<td>130,797</td>
<td>125,113</td>
<td>219,995</td>
</tr>
<tr>
<td>Grants to Princess Margaret Cancer Centre</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building</td>
<td>(3,724)</td>
<td>(8,552)</td>
<td>(6,635)</td>
<td>(8,661)</td>
<td>(16,709)</td>
</tr>
<tr>
<td>Research, Education and Patient Care</td>
<td>(89,119)</td>
<td>(95,928)</td>
<td>(93,169)</td>
<td>(92,998)</td>
<td>(90,567)</td>
</tr>
<tr>
<td>Equipment</td>
<td>(9,618)</td>
<td>(2,083)</td>
<td>(1,868)</td>
<td>(4,122)</td>
<td>(3,741)</td>
</tr>
<tr>
<td>(102,460)</td>
<td>(106,563)</td>
<td>(104,672)</td>
<td>(105,781)</td>
<td>(113,037)</td>
<td></td>
</tr>
<tr>
<td>Excess of Revenue over Expenses for the year</td>
<td>39,165</td>
<td>24,611</td>
<td>26,125</td>
<td>19,332</td>
<td>106,958</td>
</tr>
<tr>
<td>Fund Balances</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endowments</td>
<td>250,297</td>
<td>271,911</td>
<td>294,553</td>
<td>271,702</td>
<td>362,660</td>
</tr>
<tr>
<td>Restricted</td>
<td>271,819</td>
<td>260,782</td>
<td>276,936</td>
<td>325,210</td>
<td>333,390</td>
</tr>
<tr>
<td>General</td>
<td>15,143</td>
<td>20,177</td>
<td>16,506</td>
<td>10,415</td>
<td>18,235</td>
</tr>
<tr>
<td>(537,259)</td>
<td>561,870</td>
<td>587,955</td>
<td>607,337</td>
<td>714,285</td>
<td></td>
</tr>
<tr>
<td>Held By University of Toronto (as of April 30)</td>
<td>15,337</td>
<td>15,689</td>
<td>15,824</td>
<td>15,156</td>
<td>18,184</td>
</tr>
<tr>
<td>Total Capital</td>
<td>552,596</td>
<td>577,559</td>
<td>603,819</td>
<td>622,483</td>
<td>732,469</td>
</tr>
</tbody>
</table>

Notes:
1. Direct fundraising expenses represent costs for logistics, marketing, and other expenses directly related to fundraising activities, including our major events such as Enbridge® Ride to Conquer Cancer®, The Weekend to Conquer Cancer™ and our Direct Marketing programs.
2. General fundraising and administrative expenses are the overhead costs associated with running Foundation operations.

Fiscal 2021

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising, and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer in Our Lifetime.

Fulfilling our Mission

Our mission is to raise and steward funds to deliver breakthrough research, exemplary teaching, and compassionate care at the Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world.

Based on reported net fundraising revenue and lottery revenue ($116.4 million):
- Major Gifts and Bequests 45%
- Lotteries 55%
- Annual Programs 12%
- Strategic Events 3%

Grants provided to Princess Margaret Cancer Centre ($113.0 million):
- Research, Education, Patient Care 82%
- Building 12%
- Equipment 3%

Beyond funds granted this year ($113.0 million), the Foundation has multi-year research and clinical commitments in progress at Princess Margaret Cancer Centre.

Distinct revenue streams

Gross revenue (excluding investment income) of $199.1 million disclosed in the CRA T3010 form is composed of two distinct revenue streams: fundraising revenue and lottery revenue. Cost ratios associated with these streams are treated differently by the CRA.

Net revenue = $116.4 million

Fulfilling our Mission: The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising, and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer in Our Lifetime.

Year-over-year highlights

Fiscal 2021

- $116.4 million net revenue
- $113.2 million gross lottery revenue
- $39.0 million lottery prizes
- $27.8 million marketing and other expenses
- $46.4 million net lottery revenue

The PMCF lottery net return of 41.0% compares favourably to the industry average return of 34.0% based on the top charitable lotteries in Ontario. The PMCF lottery net operating margin of 6.0% is substantially lower than CRA acceptable guidelines (7.0%+).

Fundraising efficiency measure

The PMCF raised $1.29 million per full-time employee, making it one of the most efficient and effective charities in Canada.
“That day was the worst day of my life.”

Kara Thornhill had just been told she likely had cholangiocarcinoma, a very rare and highly aggressive liver cancer with a five-year survivor rate of less than 10%. At 37 years old with two young daughters and a bright teaching career ahead of her, facing cancer wasn’t part of the plan.

In March of 2017, Kara went to her family doctor to check on symptoms of intense itching, digestion issues, and fatigue. A series of tests ensued. Bloodwork and an ultrasound showed a mass, and then a CT scan and MRI confirmed the doctors’ suspicions: on May 8, 2017, she was diagnosed with cholangiocarcinoma.

Kara was told cholangiocarcinoma is a terminal cancer, as there is no one cure and the available treatments can, at best, prolong a patient’s life. As terrible as that day was, she knew she needed to focus on moving forward for her daughters, despite the odds. She remembers telling herself, “I’ve got to put one foot in front of the other. I’ve got to do this.”

Kara was then referred to The Princess Margaret, where a team of doctors had developed an experimental protocol for cholangiocarcinoma. Dr. Laura Dawson, Kara’s Radiation Oncologist at the Cancer Centre, emphasized the importance of teamwork behind this unique and very specialized treatment: “This is a multi-disciplinary effort. The liver transplant team, radiation oncology, and the medical oncology team have come together and devised a protocol (that’s) not available anywhere else in Canada.” The gruelling protocol entailed a series of tests and surgical procedures, as well as four weeks of daily radiation and chemotherapy, with the end goal of having a liver transplant. There were no guarantees, but Kara saw it as her “best chance at long-term survival.”

With her family by her side and with guidance from Dr. Dawson and the entire medical team, Kara continued moving forward. As the doctors at The Princess Margaret prepared for the transplant, her family was there to support her every step of the way, from helping with childcare and cooking meals, to taking her to appointments, and even living with her in a Toronto hotel during her rigorous radiation treatment. It was only natural, then, that Kara’s sister Tanya would step up in the most ultimate way: by volunteering to be her liver donor. “I am beyond blessed for the support and the love that I have from my family,” Kara reflects.

Family is what helped carry Kara through the entire process, and what inspired her to push back against her dire diagnosis. She became the eighth person in Canada to successfully complete The Princess Margaret’s protocol for cholangiocarcinoma. Today, Kara is NED (no evidence of disease). “When you have two human beings who depend on you, you can’t crawl into bed and cry,” Kara says, “You’ve got to keep moving.” Four years after that terrible day, against all odds, that’s exactly what she’s doing.

Click to watch Kara’s story in her own words.

Kara Thornhill with her two daughters and sister Tanya, who volunteered as her liver donor.

“Conquering the odds.

What inspired me was my kids. Living for my children. My faith in myself and in the doctors.”
# Board Committees

## The Princess Margaret Cancer Foundation

April 1, 2020 to March 31, 2021

### Board Committee Leadership Membership

<table>
<thead>
<tr>
<th>Board Committee</th>
<th>Leadership</th>
<th>Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Committee</td>
<td>Chair: Janice Fukakusa</td>
<td>Sean Boyd, Stacey Madge, Richard Rooney, Annie Ropar, Duncan Sinclair, Kevin Smith, Jochen Tilk, Stuart Waugh</td>
</tr>
<tr>
<td></td>
<td>Vice Chairs: Rohit Bhapkar, J-F Courville</td>
<td>Terry Bacinello, Michael Crackiew (Community), Janice Fukakusa, Angela McDonald (Community)</td>
</tr>
<tr>
<td></td>
<td>Ex Officio (Non-Voting):</td>
<td>Lawrence Pentland, Janice Schimmer (Research Director, PM Cancer Centre), Mark Taylor (UHN), Dr. Brad Wouters (UHN)</td>
</tr>
<tr>
<td>Audit &amp; Risk</td>
<td>Chair: Annie Ropar</td>
<td>Janice Fukakusa, Christina Kramer, Helen Malloy-Hicks, Richard Rooney, Duncan Sinclair</td>
</tr>
<tr>
<td>Commercialization</td>
<td>Chair: Stuart Waugh</td>
<td>Terry Bacinello, Michael Crackiew (Community), Janice Fukakusa, Angela McDonald (Community)</td>
</tr>
<tr>
<td></td>
<td>Vice Chairs: Rohit Bhapkar, J-F Courville</td>
<td>Ex Officio (Non-Voting): Lawrence Pentland, Janice Schimmer (Research Director, PM Cancer Centre), Mark Taylor (UHN), Dr. Brad Wouters (UHN)</td>
</tr>
<tr>
<td>Governance</td>
<td>Chair: Duncan Sinclair</td>
<td>Nancy Carroll (Community), Mary Filipelli, Janice Fukakusa, Candace Innes, Maureen Shaughnessy Kitts (Community), Donna Young</td>
</tr>
<tr>
<td>Granting, Stewardship &amp; Impact</td>
<td>Chair: Sean Boyd</td>
<td>Janice Fukakusa, Harry Goldgut, Judith Irving, Christina Kramer, Richard Rooney, Jochen Tilk, Betsy Wright (Community)</td>
</tr>
<tr>
<td></td>
<td>Ex Officio (Non-Voting):</td>
<td>Dr. Aaron Schimmer (PM Research Director), Dr. Keith Stewart (VP, Cancer), Dr. Brad Wouters (UHN VP, Research)</td>
</tr>
</tbody>
</table>

### UHN Governance Appointments

<table>
<thead>
<tr>
<th>Committee</th>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>UHN Board of Trustees</td>
<td>Board Chair</td>
<td>Janice Fukakusa</td>
</tr>
<tr>
<td>UHN Finance &amp; Audit Committee</td>
<td>Chair, Audit &amp; Risk Committee</td>
<td>Annie Ropar</td>
</tr>
<tr>
<td>UHN Research Committee</td>
<td>Chair, Granting, Stewardship &amp; Impact</td>
<td>Sean Boyd</td>
</tr>
</tbody>
</table>

---

**Human Resources Committee**

- Chair: Janice Fukakusa
- Stacey Madge
- Richard Rooney
- Humza Teherany

**Investment**

- Chair: Richard Rooney
- Terry Bacinello
- Anish Chopra (Community)
- Bob Dorrance
- Janice Fukakusa
- Stephen Goldhar (Community)
- Douglas Greaves (Community)
- Marianne Harris (Community)
- Stuart Waugh
- Aazar Zafar (Community)

**Fundraising Advisory Board**

- Chair: Jochen Tilk
- Jürgen Schreiber
- Duncan Sinclair
- Tina Tehranchian (Community)
- Michael Wilson (Community)

**Governance Chair**

- Duncan Sinclair
- Mary Filipelli
- Janice Fukakusa
- Candace Innes
- Maureen Shaughnessy Kitts (Community)
- Donna Young

**Granting, Stewardship & Impact**

- Chair: Sean Boyd
- Janice Fukakusa
- Harry Goldgut
- Judith Irving
- Christina Kramer
- Richard Rooney
- Jochen Tilt
- Betsy Wright (Community)

**Ex Officio (Non-Voting):**

- Dr. Aaron Schimmer (PM Research Director)
- Dr. Keith Stewart (VP, Cancer)
- Dr. Brad Wouters (UHN VP, Research)
Contributions reflect lifetime giving starting at $250K. Thank you to everyone who has given so generously.

Our Donors

Our Donors

Our Donors

Our Donors

OUR DONORS

20
Membership in the JCB Grant Society is offered to donors who have included The Princess Margaret in their will or have made a gift of life insurance. We are deeply grateful to the members listed here.

April 1, 2020 to March 31, 2021
April 1, 2020 to March 31, 2021

Expendable Funds List

April 1, 2020 to March 31, 2021

Expendable Funds List

27
<table>
<thead>
<tr>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Purkis Fund for Lung Cancer Research</td>
</tr>
<tr>
<td>Joseph Lome-Garin Research Fund</td>
</tr>
<tr>
<td>Joseph Robert Russell Research Fund</td>
</tr>
<tr>
<td>Junior League of Toronto Pediatric Radiation Fund</td>
</tr>
<tr>
<td>Katherine E. McLachlan Research Fund</td>
</tr>
<tr>
<td>Khoudheid Sadji Multiple Myeloma Research Fund</td>
</tr>
<tr>
<td>Lee W. and Margaret Lau Breast Cancer Research Fund</td>
</tr>
<tr>
<td>Leslie Zoe Moses Fund</td>
</tr>
<tr>
<td>Lynn-B, Joey and Sam Lyons Fund</td>
</tr>
<tr>
<td>Lynn L. King Palliative Care Fund</td>
</tr>
<tr>
<td>M. A. Allan-McMillan Research Fund</td>
</tr>
<tr>
<td>Margaret Mary Vian Endowment Fund</td>
</tr>
<tr>
<td>Margaret Pollard Research Fund</td>
</tr>
<tr>
<td>Martin H. McKerbert Research Fund</td>
</tr>
<tr>
<td>The Mary and Garth MacCallan Cancer Research Fund</td>
</tr>
<tr>
<td>Mary C. Conroy Research Fund</td>
</tr>
<tr>
<td>Mary Pawlik Fund for Research into Lung Cancer</td>
</tr>
<tr>
<td>The Mary Susan Macdonald Stomach Cancer Research Fund (Endowed)</td>
</tr>
<tr>
<td>Max Tannenbaum Music Program Fund</td>
</tr>
<tr>
<td>McDowell-Sicou Family Research Fund</td>
</tr>
<tr>
<td>Melissa Ann Katzenman Cancer Research Fund</td>
</tr>
<tr>
<td>Michael Kaim-Url Adipose Inflammation Program Fund</td>
</tr>
<tr>
<td>Michael V. and Wanda Picha Fellowship Fund</td>
</tr>
<tr>
<td>Mirdiet Early Research Fund</td>
</tr>
<tr>
<td>Mishel Goldberg Fellowship Fund</td>
</tr>
<tr>
<td>Mindy Kitch Bridge to the Cure Endowment Fund</td>
</tr>
<tr>
<td>Monica Wright Roberts National Breast Cancer Endowment Fund</td>
</tr>
<tr>
<td>Morris and Marica Kentner Fund</td>
</tr>
<tr>
<td>Montgomery-Copping Palliative Care Endowment Fund</td>
</tr>
<tr>
<td>N. B. Kessel Fellowship in Translational Research Fund</td>
</tr>
<tr>
<td>Nore and Sager Fund for Cancer Research Fund</td>
</tr>
<tr>
<td>Norman Lowesky Leukemia Fund</td>
</tr>
<tr>
<td>Onderlander Fellowship in Lung Cancer Research</td>
</tr>
<tr>
<td>Pak Heng Chu Research Fund</td>
</tr>
<tr>
<td>Paula Colosimo Fund for Drug Discovery</td>
</tr>
<tr>
<td>Pearl Banks Family Endowment in Melanoma Research and Patient Care Fund</td>
</tr>
<tr>
<td>Pencer Centre Patient and Family Advisory Committee Fund</td>
</tr>
<tr>
<td>Philip and Terry Strepenn-Otay Cancer Research Fund (Endowed)</td>
</tr>
<tr>
<td>Philip Levine Life Over Lymphoma Endowment Fund</td>
</tr>
<tr>
<td>Philip Tomo Cancer Research Endowment Fund</td>
</tr>
<tr>
<td>Philippa Sims-Harriman Lectureal Fund</td>
</tr>
<tr>
<td>Phyllis Heilman Breast Cancer Fund</td>
</tr>
<tr>
<td>Phyllis Smith Nursing Education Fund</td>
</tr>
<tr>
<td>The Rabbi Joseph and Doris Kanen Fund</td>
</tr>
<tr>
<td>Reid-Weston Family Leukemia Research Fund</td>
</tr>
<tr>
<td>Richard H. Glimm Lectureship in Head &amp; Neck Oncology Fund</td>
</tr>
<tr>
<td>Robert Vilasea Bone Marrow Fund</td>
</tr>
<tr>
<td>Roy Arthur Fasceitti Cancer Research Fund</td>
</tr>
<tr>
<td>Ryder MacDugald Family Fund</td>
</tr>
<tr>
<td>Shana's Miracle Fund</td>
</tr>
<tr>
<td>Shira B. Leifer Cancer Research Fund</td>
</tr>
<tr>
<td>Shirley Male Breast Cancer Research Fund</td>
</tr>
<tr>
<td>Spoznik Family Endowment Fund</td>
</tr>
<tr>
<td>Steven Hoffman Fellowship in Molecular Genomics</td>
</tr>
<tr>
<td>Stevens-Peter's Bridge Fellowship in Radiation Medicine Fund</td>
</tr>
<tr>
<td>Susan E. Cree Cancer Early Detection Fund</td>
</tr>
<tr>
<td>Sylva and Louise Lockshin Patient Education Program Fund</td>
</tr>
<tr>
<td>Sylvia Jazwzak Pancreatic Cancer Research Fund</td>
</tr>
<tr>
<td>TDF Fund for Medical Discovery</td>
</tr>
<tr>
<td>Teddy Cronin Cancer Research Fund</td>
</tr>
<tr>
<td>Tehmi Boman Shroff Fund Multiple Myeloma Research Fund</td>
</tr>
<tr>
<td>Terry Watson Research Fund</td>
</tr>
<tr>
<td>Tony Penella Fund</td>
</tr>
<tr>
<td>Val Tymko Sarcoma Research Fund</td>
</tr>
<tr>
<td>Valerie Dickson Fund</td>
</tr>
<tr>
<td>Vera McDermott Patient Education Fund</td>
</tr>
<tr>
<td>W. J. Collins and J.A. McNeil Research Fund</td>
</tr>
<tr>
<td>Walter B. Pope Fund</td>
</tr>
<tr>
<td>Whorton Lectureship in Head and Neck Cancer Fund</td>
</tr>
<tr>
<td>William and Dorothy Dreising and Family Ovarian Cancer Research Fund</td>
</tr>
</tbody>
</table>

To learn how you can help conquer cancer visit thepmcf.ca

Office/Courier Address: 700 University Avenue, 4th Floor, Toronto, ON M5G 1Z5
Mailing Address: 610 University Avenue, Toronto, ON M5G 2M9
Follow or Like us on social media.

Charitable Organization No. 89900 7597 RR0001

Endowed Funds List

April 1, 2020 to March 31, 2021